Skip to main content
. Author manuscript; available in PMC: 2014 Jul 29.
Published in final edited form as: Lancet Glob Health. 2013 Dec 10;2(1):23–34. doi: 10.1016/S2214-109X(13)70172-4

Figure 1.

Figure 1

The incremental cost per DALY averted for expanding ART eligibility criteria to include HIV-positive adults with CD4 ≤500 cells/µL or all HIV-positive adults, assuming continuation of status quo patterns of healthcare access. Results calculated over a 20 year time horizon, with all costs and health benefits discounted at 3% per annum. All costs reported in 2012 US dollars. Horizontal dashed lines represent cost-effectiveness benchmarks of one times and three times per capita GDP. Menzies (South Africa) and models for India only simulated eligibility for all HIV-positive adults, not restricted to those with CD4 ≤500 cells/µL. ‘*’ indicates that eligibility for CD4 ≤500 cells/µL is dominated by eligibility for all HIV-positive adults. For the Goals model in Zambia, the estimated ICER is negative because over 20 years the strategy produces health benefits and is estimated to be cost saving over 20 years due to the reduced treatment and care burden, including savings due to averted TB treatment costs.